Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

Cancer. 2000 May 1;88(9):2194-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Islet Cell / drug therapy*
  • Carcinoma, Islet Cell / surgery
  • Confidence Intervals
  • Disease Progression
  • Doxorubicin / administration & dosage*
  • Follow-Up Studies
  • Humans
  • Palliative Care
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / surgery
  • Quality of Life
  • Remission Induction
  • Streptozocin / administration & dosage*
  • Survival Rate

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Streptozocin
  • Doxorubicin